WO2007020405A3 - Integrin i-domain binding peptides - Google Patents

Integrin i-domain binding peptides Download PDF

Info

Publication number
WO2007020405A3
WO2007020405A3 PCT/GB2006/003015 GB2006003015W WO2007020405A3 WO 2007020405 A3 WO2007020405 A3 WO 2007020405A3 GB 2006003015 W GB2006003015 W GB 2006003015W WO 2007020405 A3 WO2007020405 A3 WO 2007020405A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
conditions
integrin
binding peptides
domain binding
Prior art date
Application number
PCT/GB2006/003015
Other languages
French (fr)
Other versions
WO2007020405A2 (en
Inventor
Evy Lundgren-Aakerlund
Christian Kjellman
Original Assignee
Cartela Ab
Smith Stephen Edward
Evy Lundgren-Aakerlund
Christian Kjellman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0516571A external-priority patent/GB2429012A/en
Application filed by Cartela Ab, Smith Stephen Edward, Evy Lundgren-Aakerlund, Christian Kjellman filed Critical Cartela Ab
Priority to EP06765268A priority Critical patent/EP1924595A2/en
Publication of WO2007020405A2 publication Critical patent/WO2007020405A2/en
Publication of WO2007020405A3 publication Critical patent/WO2007020405A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides novel polypeptide comprising the amino acid sequence of SEQ ID NOS: 1, 2, 3, 4 or 5, variants, fusions or derivatives thereof, and pharmaceutical formulations of the same. The peptides and formulations of the invention are useful for treating diseases or conditions capable of being treated by an agent which modulates the function of an integrin and/or a metzincin, such as arthritic diseases, inflammatory diseases and conditions and cancer. Also provided are diagnostic methods for such diseases and conditions, and methods of screening for candidate compounds with efficacy in the treatment of such diseases and conditions.
PCT/GB2006/003015 2005-08-12 2006-08-11 Integrin i-domain binding peptides WO2007020405A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06765268A EP1924595A2 (en) 2005-08-12 2006-08-11 Novel peptides and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70789505P 2005-08-12 2005-08-12
GB0516571.7 2005-08-12
GB0516571A GB2429012A (en) 2005-08-12 2005-08-12 Polypeptides capable of binding an integrin I-domain.
US60/707,895 2005-08-12

Publications (2)

Publication Number Publication Date
WO2007020405A2 WO2007020405A2 (en) 2007-02-22
WO2007020405A3 true WO2007020405A3 (en) 2007-05-03

Family

ID=37487992

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/003015 WO2007020405A2 (en) 2005-08-12 2006-08-11 Integrin i-domain binding peptides

Country Status (2)

Country Link
EP (1) EP1924595A2 (en)
WO (1) WO2007020405A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3553525A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016557A1 (en) * 1995-10-31 1997-05-09 Boehringer Ingelheim International Gmbh TREATMENT OF TUMOURS BY ADOPTIVE TRANSFER OF CD44v-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
WO1999002551A1 (en) * 1997-07-11 1999-01-21 Biotie Therapies Ltd. Integrin binding peptide and use thereof
WO2001057277A2 (en) * 2000-02-04 2001-08-09 Aeomica, Inc. Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human fetal liver
WO2003022991A2 (en) * 2001-09-07 2003-03-20 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
WO2004110477A1 (en) * 2003-06-19 2004-12-23 Ctt Cancer Targeting Technologies Oy Inhibitors of the leukocyte prommp-9/beta(2) integrin complex

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016557A1 (en) * 1995-10-31 1997-05-09 Boehringer Ingelheim International Gmbh TREATMENT OF TUMOURS BY ADOPTIVE TRANSFER OF CD44v-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
WO1999002551A1 (en) * 1997-07-11 1999-01-21 Biotie Therapies Ltd. Integrin binding peptide and use thereof
WO2001057277A2 (en) * 2000-02-04 2001-08-09 Aeomica, Inc. Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human fetal liver
WO2003022991A2 (en) * 2001-09-07 2003-03-20 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
WO2004110477A1 (en) * 2003-06-19 2004-12-23 Ctt Cancer Targeting Technologies Oy Inhibitors of the leukocyte prommp-9/beta(2) integrin complex

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BJORKLUND M ET AL: "Peptide Inhibition of Catalytic and Noncatalytic Activities of Matrix Metalloproteinase-9 Blocks Tumor Cell Migration and Invasion", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 279, no. 28, 9 July 2004 (2004-07-09), pages 29589 - 29597, XP002990968, ISSN: 0021-9258 *
DATABASE Geneseq [online] 4 February 2002 (2002-02-04), "Peptide #1939 encoded by human foetal liver single exon probe.", XP002411307, retrieved from EBI accession no. GSN:ABB34433 Database accession no. ABB34433 *
GULLBERG ET AL: "Collagen-binding I domain integrins - what do they do?", PROGRESS IN HISTOCHEMISTRY AND CYTOCHEMISTRY, GUSTAV FISCHER VERLAG, STUTTGART, DE, vol. 37, no. 1, 2002, pages 3 - 54, XP005032609, ISSN: 0079-6336 *
NYMALM YVONNE ET AL: "Jararhagin-derived RKKH peptides induce structural changes in alpha1I domain of human integrin alpha1beta1.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 9, 27 February 2004 (2004-02-27), pages 7962 - 7970, XP002411305, ISSN: 0021-9258 *
PASQUALINI R ET AL: "A PEPTIDE ISOLATED FROM PHAGE DISPLAY LIBRARIES IS A STRUCTURAL AND FUNCTIONAL MIMIC OF AN RGD-BINDING SITE ON INTEGRINS", THE JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, US, vol. 130, no. 5, September 1995 (1995-09-01), pages 1189 - 1196, XP000944635, ISSN: 0021-9525 *
STEFANIDAKIS MICHAEL ET AL: "Identification of a negatively charged peptide motif within the catalytic domain of progelatinases that mediates binding to leukocyte beta2 integrins.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 36, 5 September 2003 (2003-09-05), pages 34674 - 34684, XP002411304, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
EP1924595A2 (en) 2008-05-28
WO2007020405A2 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
WO2004074455A3 (en) Fc REGION VARIANTS
EP2154157A3 (en) FC region variants
MX348154B (en) IL-1ß BINDING ANTIBODIES AND FRAGMENTS THEREOF.
EP2374451A3 (en) Histone deacetylase inhibitors (HDAC) that correct protein misfolding and uses thereof
WO2005046709A3 (en) Tgf - beta binding and supported peptides
WO2006087637A3 (en) Anti her2/neu antibody
WO2011036443A3 (en) Si protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders
IN2012DN02981A (en)
WO2007093848A3 (en) Crystalline enoyl-(acyl-carrier-protein) reductase from heliobacter pylori
WO2003087138A3 (en) Methods for identifying polypeptide factors interacting with rna
WO2004094476A3 (en) Compositions and methods relating to stop-1
WO2007013358A3 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
DK1234025T3 (en) Human enzymes from the metalloprotease family
WO2007020405A3 (en) Integrin i-domain binding peptides
WO2005004894A3 (en) Methods for increasing cell and tissue viability
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
WO2004070012A3 (en) Cell-killing molecules and methods of use thereof
ATE485831T1 (en) TREATMENT OF NEURODEGENERATION
WO2007066018A3 (en) Novel peptides and the biological use thereof
WO2005048822A3 (en) Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
WO2007049065A3 (en) Vwfa, collagen and kunitz domain containing protein
ATE405827T1 (en) SCREENING PROCEDURE
EP1760087A4 (en) Novel protein complex and use thereof
EP3219720A3 (en) Wdrpuh epitope peptides and vaccines containing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006765268

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006765268

Country of ref document: EP